Amphetamine and negative symptoms of schizophrenia. 1996

M Sanfilipo, and A Wolkin, and B Angrist, and D P van Kammen, and E Duncan, and S Wieland, and T B Cooper, and E D Peselow, and J Rotrosen
Department of Psychiatry, New York Veterans Affairs Medical Center, 10010, USA.

The purpose of this study was to assess further the effect of amphetamine on negative symptoms of schizophrenia. Thirty-seven schizophrenic males meeting DSM-III criteria were rated with the Brief Psychiatric Rating Scale, the Abrams and Taylor Scale, and the Abnormal Involuntary Movements Scale before and after double-blind administration of either amphetamine (n = 26) or placebo (n = 11). Our results indicated that amphetamine administration generally did not improve negative symptoms, even when accounting for changes in positive symptoms. However, greater baseline negative symptoms were associated with a modest diminution after amphetamine treatment. Therefore, amphetamine may modestly improve negative symptoms in those schizophrenics in whom this symptomatology is more severe.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000661 Amphetamine A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE. Desoxynorephedrin,Levoamphetamine,Phenopromin,l-Amphetamine,Amfetamine,Amphetamine Sulfate,Amphetamine Sulfate (2:1),Centramina,Fenamine,Mydrial,Phenamine,Thyramine,levo-Amphetamine,Sulfate, Amphetamine,l Amphetamine,levo Amphetamine
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

M Sanfilipo, and A Wolkin, and B Angrist, and D P van Kammen, and E Duncan, and S Wieland, and T B Cooper, and E D Peselow, and J Rotrosen
April 1988, International clinical psychopharmacology,
M Sanfilipo, and A Wolkin, and B Angrist, and D P van Kammen, and E Duncan, and S Wieland, and T B Cooper, and E D Peselow, and J Rotrosen
January 1980, Psychopharmacology,
M Sanfilipo, and A Wolkin, and B Angrist, and D P van Kammen, and E Duncan, and S Wieland, and T B Cooper, and E D Peselow, and J Rotrosen
July 1984, Indian journal of psychiatry,
M Sanfilipo, and A Wolkin, and B Angrist, and D P van Kammen, and E Duncan, and S Wieland, and T B Cooper, and E D Peselow, and J Rotrosen
May 1984, The American journal of psychiatry,
M Sanfilipo, and A Wolkin, and B Angrist, and D P van Kammen, and E Duncan, and S Wieland, and T B Cooper, and E D Peselow, and J Rotrosen
March 1992, The Practitioner,
M Sanfilipo, and A Wolkin, and B Angrist, and D P van Kammen, and E Duncan, and S Wieland, and T B Cooper, and E D Peselow, and J Rotrosen
November 1991, The British journal of psychiatry : the journal of mental science,
M Sanfilipo, and A Wolkin, and B Angrist, and D P van Kammen, and E Duncan, and S Wieland, and T B Cooper, and E D Peselow, and J Rotrosen
June 1995, L'Encephale,
M Sanfilipo, and A Wolkin, and B Angrist, and D P van Kammen, and E Duncan, and S Wieland, and T B Cooper, and E D Peselow, and J Rotrosen
March 1987, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
M Sanfilipo, and A Wolkin, and B Angrist, and D P van Kammen, and E Duncan, and S Wieland, and T B Cooper, and E D Peselow, and J Rotrosen
June 1993, Harefuah,
M Sanfilipo, and A Wolkin, and B Angrist, and D P van Kammen, and E Duncan, and S Wieland, and T B Cooper, and E D Peselow, and J Rotrosen
August 1990, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
Copied contents to your clipboard!